QIAGEN powered by

Webinars and events

Loading Events

« All Events

  • This event has passed.

Target exploration and cell line selection for drug discovery

July 13, 2023 @ 1:00 pm - 2:30 pm

Cancer cell line models have been a cornerstone of cancer research for decades. Profiling cancer cell lines is a powerful tool to identify gene alterations or cancer-related pathways and to discover potential drug targets. This training will focus on using QIAGEN OmicSoft Lands and Ingenuity Pathway Analysis (IPA) as guides to select cell lines and translate insights gained from cell lines into discovering new possible drug targets.

In this 90-minute training, we’ll explore how you can use our platforms to:
• Select appropriate cancer cell lines for a variety of applications such as drug discovery, precision disease modeling, understanding gene function in cancer and immune-oncology research
• Examine genes of interest across various ‘omics datasets to analyze changes in expression, mutation, hotspots and gene dependency data
• Generate networks for hypotheses and test them in-silico to improve the translation of insights derived from cell line models to drug target identification
• Analyze integrated public ‘omics data and drug response phenotypes using cell line model systems by exploring data from the Library of Integrated Network-Based Cellular Signatures (LINCS)
• Prioritize drug targets and profile phenotypic/downstream effects of drug action by overlaying public data on your own generated networks

Our system uses millions of curated literature findings in the QIAGEN/ IPA Knowledge Base and the OmicSoft digital warehouse. This training is for those of you familiar with QIAGEN IPA, as well as newcomers interested in learning more.

Details

Date: July 13, 2023
Time:
 1:00 pm - 2:30 pm
Register for event
Event Categories:
,

Venue

Virtual – Americas – EST
United States
Register for event

On-demand Webinars


  • Indication expansion and drug repurposing using QIAGEN OmicSoft and Ingenuity Pathway Analysis

    Research and development for new drugs and disease treatments can be lengthy and costly. Indication expansion can help broaden the impact of a new drug that has already been through the arduous R&D process for a disease or cancer. Drug repurposing can take this concept and expand on it by looking for other diseases with similar drug target biology. The logic is if...

  • Part I: Single-cell RNA sequencing data analysis using QIAGEN CLC Genomics Workbench

    This two-part series will walk you through single-cell RNA sequencing (scRNA-seq) analysis starting with a matrix file or FASTQ files and ending with a deep understanding of key pathways, regulators and cell type signatures within your data. This session is for part I of this training. In this session, you'll learn to use QIAGEN CLC Genomics Workbench to perform se...

  • Part II: Single-cell RNA sequencing data interpretation using QIAGEN Ingenuity Pathway Analysis

    This two-part series will walk you through single-cell RNA sequencing (scRNA-seq) analysis starting with a matrix file or FASTQ files and ending with a deep understanding of key pathways, regulators and cell type signatures within your data. In this session, we'll explore how you can take your scRNA-seq differential expression results produced from QIAGEN CLC Genom...

  • Immune repertoire analysis using QIAGEN CLC Genomics Workbench

    The composition of the immune repertoire, consisting of the T cell and B cell receptors (TCR and BCR), is important for an organism's adaptive immune system and plays a pivotal role in an individual's overall health. Understanding the complex array of TCR and BCR allows for developing precision medicine and immunotherapy. Analyzing next-generation sequencing (NGS) dat...

  • Compare and contextualize your results using QIAGEN Ingenuity Pathway Analysis

    Take your QIAGEN Ingenuity Pathway Analysis (IPA) analyses to the next level by comparing them to your own analyses (different time points, treatments, cell lines, diseases and more) or to a library of over 100K precomputed datasets to find similar or opposite biological signatures. Identify key genes or entities and then explore how they are expressed across normal t...

  • Drug treatment, toxicology and target safety assessment using QIAGEN IPA and OmicSoft

    In this 90-minute training, you'll learn how to perform drug treatment, toxicology and target safety assessment-related discoveries using QIAGEN Ingenuity Pathway Analysis (IPA) and QIAGEN Omicsoft Lands. Using public data from GTEx (normal tissue), GEO, cancer collections and more, you'll learn how to use Omicsoft Lands to: • Investigate a drug target or biom...